Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Neoplasms by Histologic Type 1

Interventions

Cyclophosphamide 8fludarabine 4Rituximab 4Melphalan 3tetulomab tetraxetan lu-177 2ponatinib 2fludarabine phosphate 2entrectinib 2atezolizumab 2alectinib 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lutetium 2Etoposide 2Doxorubicin 2Busulfan 2Brentuximab Vedotin 2Bortezomib 2Bone Marrow Transplantation 2trametinib 1pertuzumab 1penpulimab 1pembrolizumab 1ibritumomab tiuxetan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × penpulimab × Lymphoid × Clear all
NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
54 enrolled
Lymphoid

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡